➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Johnson and Johnson
Baxter
Moodys
McKesson

Last Updated: July 10, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021861


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 021861 describes PATANASE, which is a drug marketed by Novartis and is included in one NDA. It is available from two suppliers. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the PATANASE profile page.

The generic ingredient in PATANASE is olopatadine hydrochloride. There are seventeen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the olopatadine hydrochloride profile page.
Summary for 021861
Tradename:PATANASE
Applicant:Novartis
Ingredient:olopatadine hydrochloride
Patents:2
Formulation / Manufacturing:see details
Pharmacology for NDA: 021861
Suppliers and Packaging for NDA: 021861
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PATANASE olopatadine hydrochloride SPRAY, METERED;NASAL 021861 NDA Alcon Laboratories, Inc. 0065-0332 0065-0332-08 1 BOTTLE in 1 CARTON (0065-0332-08) > 8 SPRAY, METERED in 1 BOTTLE
PATANASE olopatadine hydrochloride SPRAY, METERED;NASAL 021861 NDA Alcon Laboratories, Inc. 0065-0332 0065-0332-30 1 BOTTLE in 1 CARTON (0065-0332-30) > 240 SPRAY, METERED in 1 BOTTLE
Paragraph IV (Patent) Challenges for 021861
Tradename Dosage Ingredient NDA Submissiondate
PATANASE SPRAY, METERED;NASAL olopatadine hydrochloride 021861 2009-06-29

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SPRAY, METERED;NASALStrength0.665MG/SPRAY
Approval Date:Apr 15, 2008TE:ABRLD:Yes
Patent:  Start TrialPatent Expiration:Aug 2, 2023Product Flag?Substance Flag?Delist Request?Y
Patent:  Start TrialPatent Expiration:Mar 17, 2023Product Flag?Substance Flag?Delist Request?Y

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
AstraZeneca
Colorcon
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.